Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 1Recurrence 1Multiple Myeloma 1Breast Neoplasms 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × Immunoconjugates × Clear all
NCT03255070 2024-02-01

A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)

Ambrx, Inc.

Phase 1 Completed
106 enrolled
BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT03489525 2022-03-28

MEDI2228

MedImmune LLC

Phase 1 Completed
107 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡